UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

The lancet oncology, 2010-11, Vol.11 (11), p.1029-1035

2010

Volltextzugriff (PDF)

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

The New England journal of medicine, 2006-12, Vol.355 (23), p.2408-2417

2006

Volltextzugriff (PDF)

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

Blood, 2003-03, Vol.101 (6), p.2368-2373

2003

Volltextzugriff (PDF)

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

Haematologica (Roma), 2014-03, Vol.99 (3), p.458-464

2014

Volltextzugriff (PDF)

ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells

Autophagy, 2011-10, Vol.7 (10), p.1108-1114

2011

Volltextzugriff (PDF)

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

American journal of hematology, 2010-03, Vol.85 (3), p.164-170

2010

Volltextzugriff (PDF)

Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission

Journal of clinical oncology, 2009-08, Vol.27 (24), p.3987-3993

2009

Volltextzugriff (PDF)

Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS

Journal of clinical oncology, 2010-06, Vol.28 (18), p.3028-3034

2010

Volltextzugriff (PDF)

Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells

Carcinogenesis (New York), 2002-08, Vol.23 (8), p.1327-1333

2002

Volltextzugriff (PDF)

Roots of clinical resistance to STI-571 cancer therapy

Science (American Association for the Advancement of Science), 2001-09, Vol.293 (5538), p.2163-2163

2001

Volltextzugriff (PDF)

Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study

Blood, 2013-11, Vol.122 (21), p.255-255

2013

Volltextzugriff (PDF)

Tissue Microarray Cytometry Reveals Positive Impact of Homeodomain Interacting Protein Kinase 2 in Colon Cancer Survival Irrespective of p53 Function

The American journal of pathology, 2011-05, Vol.178 (5), p.1986-1998

2011

Volltextzugriff (PDF)

Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience

Journal of clinical oncology, 2005-10, Vol.23 (30), p.7676-7684

2005

Volltextzugriff (PDF)

CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation

Proceedings of the National Academy of Sciences - PNAS, 2011-11, Vol.108 (47), p.19072-19077

2011

Volltextzugriff (PDF)

Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results

Haematologica (Roma), 2007-10, Vol.92 (10), p.1327-1334

2007

Volltextzugriff (PDF)

Les Centres de lutte contre le cancer dans le paysage de la cancérologie française

Bulletin du cancer, 2013-06, Vol.100 (6), p.611-617

Reiffers, Josy

2013

Volltextzugriff (PDF)

The French Comprehensive Cancer Centers in the French oncology landscape

Bulletin du cancer, 2013-06, Vol.100 (6), p.611

Reiffers, Josy

2013

Volltextzugriff (PDF)

Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4324-4330

2002

Volltextzugriff (PDF)

Allogeneic Bone Marrow Transplantation in Multiple Myeloma

The New England journal of medicine, 1991-10, Vol.325 (18), p.1267-1273

1991

Volltextzugriff (PDF)

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Blood, 2007-04, Vol.109 (8), p.3496-3499

2007

Volltextzugriff (PDF)

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

JNCI : Journal of the National Cancer Institute, 2011-04, Vol.103 (7), p.553-561

2011

Volltextzugriff (PDF)

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Blood, 2008-09, Vol.112 (5), p.2024-2027

2008

Volltextzugriff (PDF)

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Blood, 2007-01, Vol.109 (1), p.58-60

2007

Volltextzugriff (PDF)

Flt3‐ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)‐4‐ and VLA‐5‐dependent mechanism

British journal of haematology, 2003-03, Vol.120 (5), p.782-786

2003

Volltextzugriff (PDF)

1 – 25 von 218

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(203)
Mit Volltextzugriff
(191)

Publikationsform

Sprache

Englisch
(203)
Französisch
(15)

Erscheinungsjahr

n.n

Thema

Humans
(131)
Science & Technology
(130)
Life Sciences & Biomedicine
(127)
Biological And Medical Sciences
(79)
Hematology
(77)
Female
(72)
Male
(72)
Medical Sciences
(72)
Adult
(66)
Middle Aged
(64)
Aged
(50)
Oncology
(48)
Hematologic And Hematopoietic Diseases
(34)
Adolescent
(33)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(32)
Treatment Outcome
(24)
Anesthesia. Intensive Care Medicine. Transfusions. Cell Therapy And Gene Therapy
(20)
Antineoplastic Agents
(20)
Bone Marrow Transplantation
(20)
Imatinib Mesylate
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

ATRA-induced upregulation of Beclin 1 prolongs the life span of differentiated acute promyelocytic leukemia cells

Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph‐positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study

Higher Incidence of Relapse With Peripheral Blood Rather Than Marrow As a Source of Stem Cells in Adults With Acute Myelocytic Leukemia Autografted During the First Remission

Addition of Lomustine to Idarubicin and Cytarabine Improves the Outcome of Elderly Patients With De Novo Acute Myeloid Leukemia: A Report From the GOELAMS

Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells

Roots of clinical resistance to STI-571 cancer therapy

Long Term Follow-Up After Imatinib Cessation For Patients Indeep Molecular Response: The Update Results Of The STIM1 Study

Tissue Microarray Cytometry Reveals Positive Impact of Homeodomain Interacting Protein Kinase 2 in Colon Cancer Survival Irrespective of p53 Function

Early Allogeneic Stem-Cell Transplantation for Young Adults With Acute Myeloblastic Leukemia in First Complete Remission: An Intent-to-Treat Long-Term Analysis of the BGMT Experience

CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation

Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results

Les Centres de lutte contre le cancer dans le paysage de la cancérologie française

The French Comprehensive Cancer Centers in the French oncology landscape

Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey

Allogeneic Bone Marrow Transplantation in Multiple Myeloma

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Flt3‐ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)‐4‐ and VLA‐5‐dependent mechanism

Suchergebnisse filtern